4:07 PM
 | 
Sep 13, 2017
 |  BC Extra  |  Politics & Policy

Doggett urging CMS transparency on Kymriah price

Rep. Lloyd Doggett (D-Texas) penned a letter to the Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma requesting transparency of the pricing agreement for Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN). Eight other congressmen added their signatures.

Last month, FDA approved the chimeric antigen receptor T cell (CAR T) therapy to treat patients up to 25 years old with B cell...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >